Medicare drug coverage

Multaq: 2027 Medicare Part D coverage

4,998 of 5,495 Part D plans (91%) list Multaq on their 2027 formulary, the plan's list of covered drugs (down 1 point from 2026). 65% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Multaq is number 108 by total Medicare Part D spending in 2024 ($415 million). Plans that list it most often put it on tier 3 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 2 RxNorm products for this name.

Multaq Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,102 (92%)4,998 (91%)-1 point
Prior authorization (of plans that list it)4 (0%)4 (0%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)3,073 (60%)3,263 (65%)+5 points
Any of the three (of plans that list it)3,074 (60%)3,264 (65%)+5 points
Not listed or restricted (of all plans)3,490 (63%)3,761 (68%)+5 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

Formulary tier

Multaq formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1144 (3%)107 (2%)
Tier 213 (0%)8 (0%)
Tier 32,679 (53%)3,119 (62%)
Tier 42,266 (44%)1,764 (35%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 36 of them (1%) added prior authorization, step therapy, or a quantity limit for Multaq, and 86 stopped listing it.

Multaq: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 202786 (2%)
Listed it in 2027, not in 202624 (1%)
Moved it to a higher tier49 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit36 (1%)
Added at least one of the three36 (1%)
Removed at least one of the three18 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Multaq off the formulary or list it with prior authorization, step therapy, or a quantity limit. 4 states tie for the highest share, 100%; California ranks last at 41%. States at the same share are ordered by the prior authorization or step therapy share; states equal on both shares share a rank, marked Tied.

States from most to least restrictive for Multaq, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
Tied 1Montana27100%0%+19 points
Tied 1New Hampshire25100%0%+24 points
Tied 1Vermont14100%0%+8 points
Tied 1Wyoming13100%0%+5 points
5New Mexico6894%0%+16 points
6Idaho4593%0%-1 point
7Tennessee15792%0%+4 points
8Alaska989%0%no change
9Alabama11587%0%+4 points
10Virginia14586%1%no change
11Hawaii5086%0%+3 points
Tied 12Indiana14085%0%+3 points
Tied 12Utah5385%0%+2 points
14Oklahoma8184%0%+11 points
15Maine5283%0%+7 points
16Kentucky12380%0%+1 point
Tied 17Colorado10678%0%+3 points
Tied 17Maryland4978%0%+11 points
19Ohio17376%0%+4 points
Tied 20North Dakota2673%0%+21 points
Tied 20Nebraska5173%0%+17 points
Tied 22Rhode Island2972%0%+1 point
Tied 22Florida54972%0%-3 points
Tied 22Connecticut5472%0%+4 points
Tied 22Louisiana12672%0%+8 points
Tied 22Washington11472%0%+10 points
Tied 27District of Columbia2171%0%-5 points
Tied 27Mississippi10571%0%-2 points
Tied 27Illinois13371%0%+9 points
Tied 30Georgia15170%0%+1 point
Tied 30Texas41270%0%+5 points
Tied 30West Virginia7070%0%+12 points
Tied 30Arkansas8670%0%-1 point
Tied 30Delaware4370%0%+8 points
Tied 30Arizona14870%0%+5 points
36North Carolina17769%0%+1 point
37South Carolina9168%0%-5 points
38Missouri17167%0%-2 points
Tied 39New York21566%0%+10 points
Tied 39Wisconsin9766%0%+5 points
Tied 39Iowa6466%0%+1 point
42Oregon9263%1%+19 points
Tied 43South Dakota3063%0%+16 points
Tied 43Kansas8463%0%no change
45Michigan18357%0%+1 point
Tied 46New Jersey7455%0%+3 points
Tied 46Pennsylvania32455%0%+19 points
Tied 46Nevada10055%0%+5 points
49Minnesota6354%0%+23 points
50Massachusetts9245%0%-4 points
51California39741%0%-1 point

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Multaq off or restrict it.

Multaq coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
CoxHealth3100%0%0%no change0
First Sacramento Capital Funding LLC3100%100%100%no change0
Imperial Health Plan of California3100%100%100%+100 points2
Liberty Healthcare Insurance3100%100%100%no change0
Marquis Companies I, Inc.3100%100%100%no change0
McLaren Health Care Corporation3100%0%0%no change0
MedCare Partners Holding, LLC3100%0%0%new in 20270
Mercy Care3100%100%100%no change0
New York City Health and Hospitals Corporation3100%100%100%no change0
Presbyterian Healthcare Services3100%100%100%no change0
SIHO Holding, Inc.3100%0%0%no change0
St. Luke's Health System, Inc.3100%0%0%new in 20270
VISITING NURSE ASSOCIATION OF CENTRAL NEW YORK3100%0%0%no change0
Village Care of New York, Inc.3100%0%0%no change0
Visiting Nurse Service of New York3100%0%0%no change0
Chapters CareNu Inc4100%100%100%no change0
Chinese Hospital Association4100%0%0%no change0
El Paso County Hospital District4100%100%100%no change0
Elderplan, Inc.4100%100%100%no change0
Horizon Mutual Holdings, Inc475%0%25%+16 points0
LMC Family Holdings, LLC4100%100%100%+100 points4
Montage Health4100%0%0%no change0
St Francis Health System & St John Health System4100%100%100%no change0
Blue Cross & Blue Shield of Rhode Island5100%0%0%no change0
BlueCross BlueShield of Alabama580%0%20%+9 points0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.